Sign in
4

Changes in Ownership

IONIS PHARMACEUTICALS INC Filed Acc 0000874015-25-000277

EVP, Chief Development Officer sold 34,639 shares at an average $75.69 ($2,621,816)

  • EVP, Chief Development Officer acquired 34,639 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Geary Richard S · EVP, Chief Development Officer

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2025-11-05 Exercise or conversion : show line 1 in the form 10b5-1 +800 $56.78 $45,424 60,457 D
2025-11-05 Sale : show line 2 in the form 10b5-1 −800 $75.01 $60,008 59,657 D
2025-11-05 Exercise or conversion : show line 3 in the form 10b5-1 +801 $60.89 $48,773 60,458 D
2025-11-05 Sale : show line 4 in the form 10b5-1 −801 $75.01 $60,083 59,657 D
2025-11-06 Exercise or conversion : show line 5 in the form 10b5-1 +14,738 $56.78 $836,824 74,395 D
2025-11-06 Sale : show line 6 in the form 10b5-1 −14,738 $76.10 $1,121,521 59,657 D
2025-11-06 Exercise or conversion : show line 7 in the form 10b5-1 +18,300 $60.89 $1,114,287 77,957 D
2025-11-06 Sale : show line 8 in the form 10b5-1 −18,300 $75.42 $1,380,204 59,657 D
Open-market sales · 34,639 sh · avg $75.69 · $2,621,816

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2025-11-05 Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −800 14,738 D
2025-11-06 Exercise or conversion : show line 10 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −14,738 0 D
2025-11-05 Exercise or conversion : show line 11 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −801 18,300 D
2025-11-06 Exercise or conversion : show line 12 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −18,300 0 D
Loading xslF345X05/edgardoc.xml…